Cita APA (7a ed.)
Reitkopp, J., Samlowski, W., & Hasan, M. (2026). Incidence and Clinical Impact of Endocrinopathy Following First-Line Nivolumab-Plus-Relatlimab Therapy for Metastatic Melanoma. Cancers, 18(14), 2349-2362.
Cita Chicago Style (17a ed.)
Reitkopp, Julia, Wolfram Samlowski, y Mahir Hasan. "Incidence and Clinical Impact of Endocrinopathy Following First-Line Nivolumab-Plus-Relatlimab Therapy for Metastatic Melanoma." Cancers 18, no. 14 (2026): 2349-2362.
Cita MLA (9a ed.)
Reitkopp, Julia, et al. "Incidence and Clinical Impact of Endocrinopathy Following First-Line Nivolumab-Plus-Relatlimab Therapy for Metastatic Melanoma." Cancers, vol. 18, no. 14, 2026, pp. 2349-2362.
Precaución: Estas citas no son 100% exactas.